Peringatan Keamanan

Oral, rat: LD50 = 1250 mg/kg.

Propylthiouracil

DB00550

small molecule approved investigational

Deskripsi

A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)

Struktur Molekul 2D

Berat 170.232
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 2 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Well absorbed following oral administration.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Propylthiouracil is readily absorbed and is extensively metabolized. Approximately 35% of the drug is excreted in the urine, in intact and conjugated forms, within 24 hours.

Interaksi Makanan

1 Data
  • 1. Take at the same time every day.

Interaksi Obat

817 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Propylthiouracil.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Propylthiouracil.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Propylthiouracil.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Propylthiouracil.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Propylthiouracil.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Propylthiouracil.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Propylthiouracil.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Propylthiouracil.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Propylthiouracil.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Propylthiouracil.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Propylthiouracil.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Propylthiouracil.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Propylthiouracil.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Propylthiouracil.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Propylthiouracil.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Propylthiouracil.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Propylthiouracil.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Propylthiouracil.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Propylthiouracil.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Propylthiouracil.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Propylthiouracil.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Propylthiouracil.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Propylthiouracil.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Propylthiouracil.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Propylthiouracil.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Propylthiouracil.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Propylthiouracil.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Propylthiouracil.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Propylthiouracil.
Cladribine Propylthiouracil may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Propylthiouracil.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Propylthiouracil.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Propylthiouracil.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Propylthiouracil.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Propylthiouracil.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Propylthiouracil.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Propylthiouracil.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Propylthiouracil.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Propylthiouracil.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Propylthiouracil.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Propylthiouracil.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Propylthiouracil.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Propylthiouracil.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Propylthiouracil.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Propylthiouracil.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Propylthiouracil.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Propylthiouracil.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Propylthiouracil.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Propylthiouracil.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Propylthiouracil.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Propylthiouracil.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Propylthiouracil.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Propylthiouracil.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Propylthiouracil.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Propylthiouracil.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Propylthiouracil.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Propylthiouracil.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Propylthiouracil.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Propylthiouracil.
Pentostatin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pentostatin.
Methotrexate The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Methotrexate.
Carbamazepine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Carbamazepine.
Vinblastine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Vinblastine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluticasone propionate.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluocinolone acetonide.
Linezolid The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Linezolid.
Triamcinolone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Triamcinolone.
Clofarabine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Clofarabine.
Prednisone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Prednisone.
Pemetrexed The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pemetrexed.
Fludrocortisone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fludrocortisone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mycophenolate mofetil.
Daunorubicin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Daunorubicin.
Irinotecan The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Irinotecan.
Methimazole The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Methimazole.
Etoposide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Etoposide.
Sulfasalazine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Penicillamine.
Prednisolone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Prednisolone.
Sirolimus The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Sirolimus.
Mechlorethamine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Carboplatin.
Methylprednisolone The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Methylprednisolone.
Dactinomycin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Azathioprine.
Doxorubicin The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Doxorubicin.
Hydroxyurea The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Topotecan.
Thalidomide The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Flucytosine.
Capecitabine The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Capecitabine.
Trilostane The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Trilostane.

Target Protein

Type I iodothyronine deiodinase DIO1
Thyroid peroxidase TPO

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 27 • International brands: 13
Produk
  • Apo-propylthiouracil
    Tablet • 50 mg • Oral • Canada • Generic • Approved
  • Apo-propylthiouracil
    Tablet • 100 mg • Oral • Canada • Generic • Approved
  • Halycil
    Tablet • 50 mg • Oral • Canada • Approved
  • PMS-propylthiouracil
    Tablet • 50 mg • Oral • Canada • Generic • Approved
  • PMS-propylthiouracil
    Tablet • 100 mg • Oral • Canada • Generic • Approved
  • Propyl-thyracil
    Tablet • 50 mg • Oral • Canada • Approved
  • Propyl-thyracil
    Tablet • 100 mg • Oral • Canada • Approved
  • Propylthiouracil
    Tablet • 50 mg/1 • Oral • US • Generic • Approved
Menampilkan 8 dari 27 produk.
International Brands
  • Antiroid — Bu Kwang
  • Propil — Pfizer
  • Propilracil — Biolab
  • Propycil — Admeda
  • Proracyl — Genopharm
  • Prothiucil — Phafag
  • Prothuril — Uni-Pharma
  • PTU — Alkaloid
  • Thiuragyl — Tanabe Mitsubishi Pharma
  • Thyrosan — Sun-Farm

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul